Back to Search
Start Over
TNF-alpha inhibitors and ustekinumab for the treatment of psoriasis: therapeutic utility in the era of IL-17 and IL-23 inhibitors.
- Source :
- Journal of psoriasis and psoriatic arthritis; vol 7, iss 2, 79-92; 2475-5303
- Publication Year :
- 2022
-
Abstract
- Psoriasis is a chronic inflammatory condition for which eleven FDA-approved biologic therapies are approved. Over the past decade, studies have documented the higher efficacy of IL-17 and IL-23 inhibitors for the treatment of psoriasis compared to the TNF-alpha inhibitors and ustekinumab, an IL-12/23 inhibitor. Despite this, there remains an important role for the use of TNF-alpha inhibitors and ustekinumab in the treatment of psoriasis. Here, we review how considerations of infection and malignancy risk, patient demographics, treatment resistance, and co-morbidities may make certain TNF-alpha inhibitors or ustekinumab an excellent choice for therapy in particular patient subgroups.
Details
- Database :
- OAIster
- Journal :
- Journal of psoriasis and psoriatic arthritis; vol 7, iss 2, 79-92; 2475-5303
- Notes :
- application/pdf, Journal of psoriasis and psoriatic arthritis vol 7, iss 2, 79-92 2475-5303
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1391590459
- Document Type :
- Electronic Resource